Evidence Hub

Aztreonam-Avibactam Successfully Treated Severe Stenotrophomonas maltophilia Infection After Allogeneic Transplantation: A Case Report and Literature Reviews

Wang H, Song J, Liu H, Hao S, Pang C, Fu R

Journal of blood medicine, 2026

Abstract

Background: Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation is rare and dangerous, especially bloodstream infection, with an extremely high mortality rate.

Case presentation: In this study, we present a case of acute T-lymphoblastic leukemia developed Stenotrophomonas maltophilia sepsis on the 8th day after allogeneic hematopoietic stem cell transplantation, accompanied by severe infections of the skin and soft tissues, pharynx, and gastrointestinal tract. After anti-infective treatment with aztreonam-avibactam, the patient's infection was effectively controlled. Neutrophil engraftment occurred on day 19 and platelet engraftment on day 30 post-transplantation. The patient was smoothly transferred from the transplant ward to a general ward.

Conclusion: Aztreonam-avibactam may have a very good clinical effect on patients with severe and multi-site Stenotrophomonas maltophilia infections.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free